Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office is conducting market research for manufacturing capability for the nerve agent antidotes atropine and 2-pralidoxime, in a single autoinjector for intramuscular administration by the U.S. military.
The DoD currently procures the nerve agent antidotes atropine and 2-pralidoxime as components of the Antidote Treatment Nerve Agent Autoinjector (ATNAA), the replacement for the two injector MARK-1 nerve agent antidote kits. The ATNAA is a self-contained unit designed for self- or buddy-administration by military personnel.
Currently, MCS-CDP is seeking capabilities from potential sources for development of an autoinjector drug-delivery device that will simultaneously or sequentially deliver the nerve agent antidotes atropine and 2-PAM. These life-saving antidotes are used in conjunction with the pretreatment, pyridostigmine bromide (PB), and an anticonvulsant.
The delivery device platform and antidotes must be stable at operationally relevant temperatures to include temperature extremes experienced by service members in the field. The storage conditions and shelf life must be equal to standards of the current ATNAA and be administrable by self- and buddy-aid in Mission Oriented Protective Posture 4 (MOPP-4) gear.
As such, MCS-CDP is seeking information on current industry capabilities from interested entities. Further details are available under Solicitation Number: W911QY-14-S-CDP1. The response deadline is November 4, 2013.
